Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
The search for non‐invasive systemic biomarkers of response to PD‐L1/PD‐1 blockade immunotherapy is currently a priority in oncoimmunology. In contrast to classical tumor biomarkers, the identification of clinically useful immunological biomarkers is certainly a challenge, as anti‐cancer immune resp...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-09-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.202012706 |